Valuation: Regulus Therapeutics Inc.

Market Cap 617M 542M 499M 467M 876M 58.18B 895M 6B 2.32B 28.72B 2.32B 2.27B 99.76B P/E 2023
-0.81x
P/E 2024 -1.92x
Enterprise Value 542M 476M 439M 411M 770M 51.14B 786M 5.27B 2.04B 25.24B 2.04B 1.99B 87.68B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
90.92%
Yield 2023 *
-
Yield 2024 -
3 years 0.83
Extreme 0.8301
8.34
5 years 0.76
Extreme 0.76
8.89
10 years 0.76
Extreme 0.76
510
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2025-06-24
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member - 2025-06-23
Director/Board Member - 2025-06-24
Date Insider Type Main position Quantity % Market Cap.
25-06-24Tender

Director

450,144 0.6872%
25-06-24Issuer sale

Director

217,475 0.3320%
25-06-24Issuer sale

Chief Executive Officer

4,963,534 7.5779%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-.--%-.--%+508.96% 617M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.13%+4.30%+38.03%+171.11% 22.69B
Weighted average by Cap. +0.26%+5.12%+48.37%+121.29%

Financials

2023 2024
Net sales - -
Net income -30.04M -26.39M -24.32M -22.75M -42.63M -2.83B -43.55M -292M -113M -1.4B -113M -110M -4.86B -46.36M -40.73M -37.53M -35.12M -65.8M -4.37B -67.21M -451M -175M -2.16B -174M -170M -7.5B
Net Debt -20.66M -18.16M -16.73M -15.65M -29.33M -1.95B -29.96M -201M -77.82M -962M -77.6M -75.9M -3.34B -74.72M -65.65M -60.49M -56.6M -106M -7.05B -108M -727M -281M -3.48B -281M -274M -12.08B
Logo Regulus Therapeutics Inc.
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Employees
34
  1. Stock Market
  2. Stocks
  3. RGLS Stock